Athersys Inc. (Nasdaq: ATHX) reported disappointing results from a mid-stage clinical trial of its refractory ulcerative colitis treatment MultiStem cell therapy. Shares of the biotechnology company plummeted $1.40 to close at $1.33.
Disappointing Trial Results For Athersys
April 28, 2014 at 17:41 PM EDT
